Cellply wins the €300k Gaetano Marzotto prize and Unicredit StartLab prize

ROME, ITALY, November 22, 2018:

Cellply has been awarded with the prestigious Gaetano Marzotto prize and received an €300,000 grant and an assistance programme from the CUOA Business School. The award ceremony was held at the MAXXI museum in Rome. The Company Prize awarded to Cellply comes after a tough selection process, as more than 600 companies applied to the competition.

During the ceremony, Cellply was also awarded with the Unicredit StartLab Special Prize, a programme providing coaching, training and support to high-tech startup companies.

The jury selected Cellply for the motivation, high competence and commitment of its team having the ambition to make a change in the way cancer patients are treated worldwide and in speeding up the drug development process. The project, if successful, will have the potential to demonstrate the quality and value of Italian research and entrepreneurship.

Cellply develops an innovative in-vitro diagnostic system to predict the efficacy of anticancer drugs with a personalized test that analyzes the in-vitro drug response of living cells quickly obtained from patient biopsies.

The Gaetano Marzotto prize, at its 8th edition, aims at looking for new business people and builders of the future who are able to combine innovation, business and social impact.

Cellply selected as finalist at Lyfebulb Oncology Award

MONACO, PRINCIPALITY OF MONACO, NEW YORK, NY, and BOLOGNA, ITALY, March 1, 2018:

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, have announced today that Cellply has been selected as one the eleven finalist companies for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. The Lyfebulb-Helsinn Innovation Summit & Award final event will be hosted on 26-27 March 2018, by Lyfebulb and Helsinn at the Monte-Carlo Bay Hotel and Resort, in Monaco, Principality of Monaco.

Read the full story here

Cellply abstract accepted at the AACR 2018 Annual Meeting

Bologna (Italy), 4 February 2018

Cellply will present results of clinical testing activities on Acute Myeloid Leukemia patients at the American Association for Cancer Research (AACR) 2018 Annual Meeting, taking place April 14-18 in Chicago.

Results of the study, conducted in collaboration with haematologists and researchers at the Sant’Orsola-Malpighi Polyclinic in Bologna, show the high accuracy obtained with Cellply’s platform in predicting standard therapy outcome.

Title: Lab-on-a-chip-based in-vitro functional profiling proves to be effective in predicting therapy outcome in AML patients
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 3613
Date/Time: Tuesday Apr 17, 2018 8:00 AM – 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 25
Session Category: Clinical Research
Session Title: Biomarker Discovery 4

Link to abstract

View poster online

Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting

Bologna (Italy), 4 November 2016.

Cellply announced today that the results of a scientific collaboration with hematologists at Seragnoli Institute of Sant’Orsola Polyclinic in Bologna (Italy) working on Acute Myeloid Leukemia (AML), a group led by Prof. Giovanni Martinelli, will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH), on December 3-6 in San Diego, CA, USA. “This is a key milestone for our company as it shows the potential of the Open Microwell technology and the IVD platform under development at Cellply to become an important tool for guiding the identification of the appropriate treatment for each patient or patient set through the analysis of biological information that today remain mostly not exploited for patient stratification”, says Massimo Bocchi, CEO of Cellply. “The preliminary data collected within this scientific activity provided good correlation between our test and the clinical outcome, making Cellply’s platform promising for predicting the haematological response, an endpoint of primary importance not only from a clinical standpoint but also for its use within clinical trials”, added Laura Rocchi, Head of Biology at Cellply. The following abstract was accepted for poster presentation by the American Society of Hematology.

Title: Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 1675
Date/Time: Saturday, December 3, 2016, 5:30 PM-7:30 PM
Location: Hall GH (San Diego Convention Center)
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Link to abstract on Blood Journal